Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L F Eichenfield

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The British Journal of Dermatology|January 17, 2007
A systematic review of the safety of topical therapies for atopic dermatitisJ Callen, S Chamlin, L F Eichenfield, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 8, 2016
Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatmentD Ovejero, Y H Lim, A M Boyce, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|April 16, 2003
International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategiesC Ellis, T Luger, D Abeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 18, 2023
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent eventsR Bissonnette, L F Eichenfield, E Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2019
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinionJ P Thyssen, M S de Bruin-Weller, A S Paller, et al.
The British Journal of Dermatology|February 6, 2019
TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registriesF M Vermeulen, L A A Gerbens, A L Bosma, et al.
The British Journal of Dermatology|May 16, 2018
TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registriesL A A Gerbens, C J Apfelbacher, A D Irvine, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The British Journal of Dermatology|January 17, 2007
A systematic review of the safety of topical therapies for atopic dermatitisJ Callen, S Chamlin, L F Eichenfield, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 8, 2016
Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatmentD Ovejero, Y H Lim, A M Boyce, et al.
The British Journal of Dermatology|September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension studyM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|April 16, 2003
International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategiesC Ellis, T Luger, D Abeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 18, 2023
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent eventsR Bissonnette, L F Eichenfield, E Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2019
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinionJ P Thyssen, M S de Bruin-Weller, A S Paller, et al.
The British Journal of Dermatology|February 6, 2019
TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registriesF M Vermeulen, L A A Gerbens, A L Bosma, et al.
The British Journal of Dermatology|May 16, 2018
TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registriesL A A Gerbens, C J Apfelbacher, A D Irvine, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.
Pageof 8